Journal
ACTA HAEMATOLOGICA
Volume 128, Issue 2, Pages 113-118Publisher
KARGER
DOI: 10.1159/000338560
Keywords
Blood transfusion; Deferasirox; Iron overload; Oral chelation therapy; Sickle cell anemia
Categories
Funding
- Novartis Oncology, Brazil
Ask authors/readers for more resources
The efficacy and safety of a 2-year treatment with deferasirox was evaluated in 31 patients with sickle cell anemia and transfusional iron overload. At 24 months, there were significant decreases from baseline in mean serum ferritin (from 2,344.6 to 1,986.3 mu g/l; p = 0.040) and in mean liver iron concentration (from 13.0 +/- 5.4 to 9.3 +/- 5.7 mg Fe/g dry weight; p < 0.001). Myocardial T2* values were normal (>20 ms) in all patients at baseline and did not change significantly over the course of the study. However, there was a significant improvement from baseline in left ventricular ejection fraction at 24 months (62.2-64.6%; p = 0.02). Deferasirox was generally well tolerated with no progressive increases in serum creatinine or renal failure observed. These data confirm that deferasirox is effective in reducing body iron burden in patients with sickle cell anemia and transfusional iron overload. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available